A reference to lab values, and to who sets the targetsHow we verifyHidden costsDealsAbout
OptimizeBiomarkers

Sources/Institution or study

2018 AHA/ACC cholesterol guideline

Named as the source for 5 optimal-range positions across 5 biomarkers on this site. How we verify ranges.

01

Every position on this site

One row per marker. The comparison column uses the same simple-range parser the rest of the site does, so it is left blank rather than guessed when a range is tiered, sex-split, or in a different unit than the lab interval.

MarkerTheir rangeVs. the lab reference intervalWhere they stated it
Apolipoprotein B (ApoB)≥130 mg/dL is a risk-enhancing factornot directly comparableCited document ↗Corresponds to an LDL-C of 160 mg/dL or more; the guideline suggests measuring ApoB when triglycerides are 200 mg/dL or higher
LDL Cholesterol≥70 mg/dL on a statin prompts add-on therapy in very high-risk ASCVDnot directly comparableCited document ↗Sets treatment thresholds rather than an optimal level; LDL-C of 190 mg/dL or more is treated without calculating risk
Lipoprotein (a)≥50 mg/dL (≥125 nmol/L) is a risk-enhancing factornot directly comparableCited document ↗Measurement is relatively indicated with a family history of premature ASCVD
TriglyceridesPersistent ≥175 mg/dL is a risk-enhancing factornot directly comparableCited document ↗
hs-CRP (High Sensitivity C-Reactive Protein)≥2.0 mg/L is a risk-enhancing factornot directly comparableCited document ↗Used to refine a borderline or intermediate 10-year risk estimate

5 verified positions shown. Every row above either links to the optimal-ranges document named in our biomarker data or passed the expert-range verification described here; unverified or withheld claims never render.

Not medical advice. © 2026 Ocean Path Ventures LLC.

The monthly dispatch

Price changes, new sources, corrected ranges.

Once a month. Every change we made to the site, and why.